Australia markets close in 1 hour 30 minutes

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
37.49+0.40 (+1.08%)
At close: 04:00PM EDT
37.49 0.00 (0.00%)
After hours: 04:15PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.83B
Enterprise value 2.14B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.19
Enterprise value/revenue 10.87k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.23
52-week change 3-3.95%
S&P500 52-week change 326.24%
52-week high 350.99
52-week low 327.99
50-day moving average 339.87
200-day moving average 340.10

Share statistics

Avg vol (3-month) 3358.41k
Avg vol (10-day) 3403.77k
Shares outstanding 575.47M
Implied shares outstanding 675.47M
Float 869.68M
% held by insiders 10.38%
% held by institutions 1100.72%
Shares short (15 May 2024) 42.82M
Short ratio (15 May 2024) 48.39
Short % of float (15 May 2024) 43.76%
Short % of shares outstanding (15 May 2024) 43.73%
Shares short (prior month 15 Apr 2024) 42.62M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-17.09%
Return on equity (ttm)-23.95%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -220.26M
Net income avi to common (ttm)-188.6M
Diluted EPS (ttm)-2.72
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)699.6M
Total cash per share (mrq)9.27
Total debt (mrq)10.43M
Total debt/equity (mrq)1.17%
Current ratio (mrq)31.82
Book value per share (mrq)11.76

Cash flow statement

Operating cash flow (ttm)-154.09M
Levered free cash flow (ttm)-105.75M